Press Releases OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Market Closed - OTC Markets Other stock markets 01:02:33 2024-04-29 pm EDT			5-day change	1st Jan Change
0.0003 ^USD	+50.00%		-.--%	-.--%

2023	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
2023	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OncoSec Medical Incorporated : Bankruptcy - Form 8-K	23-06-14	PU
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-06-02	AQ
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	23-05-18	PR
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	23-05-16	PR
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program	23-05-16	PR
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	23-04-27	AQ
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program	23-04-27	PR
ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	23-04-11	AQ
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	23-04-11	PR
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	23-04-10	PR
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	23-04-04	AQ
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	23-04-03	AQ
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	23-04-03	PR
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	23-03-14	AQ
Methes Energies International Ltd ($MEIL) enters into the b2 biOil and bio-lubricant sector via acquisition of EarthFriendly Products Inc	23-03-02	AQ
ONCOSEC MEDICAL INC : Other Events (form 8-K)	23-02-22	AQ
ONCOSEC MEDICAL INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-01-04	AQ
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22-12-28	AQ
ONCOSEC MEDICAL INC : Change in Directors or Principal Officers (form 8-K)	22-12-27	AQ
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	22-12-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Press Releases

Filters